Zydus Lifesciences Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Zydus Lifesciences Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Zydus Lifesciences Ltd. from all sources in a single place.

Load latest

Zydus Lifesciences Ltd.

11 Feb 2022

1034.50

-0.23%

Corp. Note

CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

pdf

Zydus Lifesciences Ltd.

10 Feb 2022

1034.50

-0.23%

Company Update

CADILA HEALTHCARE LTD. - 532321 - Transcript

BSE India

Transcript of investor call held on February 3, 2022

pdf

Zydus Lifesciences Ltd.

09 Feb 2022

1034.50

-0.23%

CADILA HEALTH CARE LIMITED

Buy: Zydus Lifesciences Ltd.

Target

Geojit BNP Paribas

Cadila Healthcare is India's leading vertically integrated pharmaceutical company. With its presence across the value chain, it manufactures finished dosage forms, active pharmaceutical ingredients, animal healthcare...

Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.

Zydus Lifesciences Ltd.

07 Feb 2022

1034.50

-0.23%

Accumulate Cadila Healthcare; target of Rs 445: KR Choksey

Moneycontrol

KR Choksey recommended accumulate rating on Cadila Healthcare with a target price of Rs 445 in its research report dated February 07, 2022.

Zydus Lifesciences Ltd. is trading above all available SMAs

Zydus Lifesciences Ltd.

05 Feb 2022

1034.50

-0.23%

Corp. Note

CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / …

BSE India

Loss of share certificate

pdf

Zydus Lifesciences Ltd.

04 Feb 2022

1034.50

-0.23%

Buy Cadila Healthcare; target of Rs 560: Sharekhan

Moneycontrol

Sharekhan is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 560 in its research report dated February 03, 2022.

Zydus Lifesciences Ltd. is trading above all available SMAs

Buy Cadila Healthcare; target of Rs 490: Motilal Oswal

Moneycontrol | 04 Feb 2022 4 more

Zydus Lifesciences Ltd.

04 Feb 2022

1034.50

-0.23%

Company Update

CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication with regard to publication of extracts of unaudited financial results for the quarter / nine months ended on December 31, 2021

pdf

Zydus Lifesciences Ltd.

04 Feb 2022

1034.50

-0.23%

Moneycontrol

The Moraiya plant's pending USFDA approval is crucial for Cadila's US ambition

Geojit BNP Paribas increased Buy price target of Zydus Lifesciences Ltd. to 1121.0 on 03 Sep, 2025.

Zydus Lifesciences Ltd.

04 Feb 2022

1034.50

-0.23%

Miss in 3Q; US / higher RM costs drag down earnings

Buy: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Cadila Healthcare (CDH) delivered lower-than-expected 3QFY22 earnings, weighed by lower Domestic Formulation (DF) / US / EM sales and increased operational costs. CDH continues its effort to build the product pipeline and niche launches (including g-Revlimid) for the US market. Even innovation-led products are advancing well in the respective clinical stages of development. We cut our EPS estimates by 2%/4%/4% for FY22E/FY23E/FY24E and reduce PE multiple to 21x (from 25x earlier) to factor in a) moderate growth in the US business over the medium term and b) the weaker outlook on the...

Geojit BNP Paribas increased Buy price target of Zydus Lifesciences Ltd. to 1121.0 on 03 Sep, 2025.

Zydus Lifesciences Ltd.

04 Feb 2022

1034.50

-0.23%

Cadila Healthcare Limited

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

In the last two years, KNL has increased its total paint manufacturing capacity by 28% to 5.3 lakh tonnes at an investment of ~| 1100 crore Q3FY22 Results: Lower industrial volume offtake and delay in passing of higher...

Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.

Is Cadila Healthcare Ltd. worth buying?

859 Votes:

Buy 81.84%

Sell 9.9%

Hold 8.27%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf